JCI – Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Posted by: admin Categories: Covid19

Ravindra Ganesh,¹

Colin F. Pawlowski,²

John C. O'Horo,³

Lori L. Arndt,⁴

Richard F. Arndt,⁵

Sarah Bell,⁶

Dennis M. Bierle,¹

Molly Destro Borgen,⁷

Sara Hanson,⁸

Alexander Heyliger,⁹

Jennifer L. Larsen,⁶

Patrick J. Lenehan,¹⁰

Robert Orenstein,¹¹

Arjun Puranik,²

Leigh L. Speicher,¹²

Sidna M. Tulledge-Scheitel,¹³

AJ Venkatakrishnan,²

Caroline G. Wilker,¹⁴

Andrew D. Badley,³ and

Raymund R. Razonable¹⁵

Published August 19, 2021
-

More info

BACKGROUND. Clinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed.

METHODS. 2,335 patients who received single-dose bamlanivimab infusion between November 12, 2020 to February 17, 2021 were compared with a propensity-matched control of 2,335 untreated patients with mild to moderate COVID-19 at Mayo Clinic facilities across 4 states. The primary outcome was the rate of hospitalization at days 14, 21 and 28.

RESULTS. The median age of the population was 63; 47.3% of the bamlanivimab-treated cohort were ≥65 years; 49.3% were female. High-risk characteristics included hypertension (54.2%), body mass index ≥35 (32.4%), diabetes mellitus (26.5%), chronic lung disease (25.1%), malignancy (16.6%), and renal disease (14.5%). Patients who received bamlanivimab had lower all-cause hospitalization rates at days 14 (1.5% vs 3.5%; Odds Ratio [OR], 0.38), 21 (1.9% vs 3.9%; OR, 0.46), and 28 (2.5% vs 3.9%; OR, 0.61). Secondary exploratory outcomes included lower intensive care unit admission rates at days 14 (0.14% vs 1%; OR, 0.12), 21 (0.25% vs 1%; OR: 0.24) and 28 (0.56% vs 1.1%; OR: 0.52), and lower all-cause mortality at days 14 (0% vs 0.33%), 21 (0.05% vs 0.4%; OR,0.08) and 28 (0.11% vs 0.44%; OR, 0.01). Adverse events were uncommon with bamlanivimab, occurring in 19/2355, most commonly fever (n=6), nausea (n=5), and lightheadedness (n=3).

CONCLUSIONS. Among high-risk patients with mild to moderate COVID-19, treatment with bamlanivimab was associated with a statistically significant lower rate of hospitalization compared with usual care.

FUNDING. Mayo Clinic.

Supplemental material

Version history

Version
1
(August 19, 2021):
In-Press Preview

Source link

Home

How To Start

Q&A

Login

JCI – Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

Latest Tweets

ABOUT

TECHNOLOGY

CLINICAL USE

COLLABORATION

REFERENCE

IN MEDIA

Home

How To Start

Products

Breathing+ Package

Toys Package

Q&A

Login

JCI – Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19

You may also like...

First coronavirus mutation resistant to antiviral drug remdesivir discovered

Emmes completes third ACTT clinical trial for COVID

Antibiotics | Free Full-Text | Efficacy and Safety of Remdesivir over Two Waves of the SARS-CoV-2 Pandemic

Latest Tweets

ABOUT

TECHNOLOGY

CLINICAL USE

COLLABORATION

REFERENCE

IN MEDIA